Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Auriga Laboratories has signed a co-promotion agreement with MiddleBrook Pharmaceuticals, pursuant to which Auriga will co-promote Keflex 750mg capsules to Primary Care Specialists in the US.
Subscribe to our email newsletter
The co-promotion will begin during the first quarter of 2008. Cephalexin, the generic form of Keflex, is said to be the number-one recommended oral antibiotic therapy for uncomplicated skin and skin structure infections.
Philip Pesin, CEO of Auriga, said: “This agreement solidifies Auriga’s commitment to enhance our product portfolio.”